title: Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells.
abstract: Antigen 90K is produced by several tumor-cell lines and by patients with cancer. Its function has not yet been clarified, although recent reports suggest that it plays a role in the tumor-host relationship--for example by stimulation of natural killer and lymphokine-activated killer-cell activity. Previous studies have indicated that 90K expression may be under the influence of interferon-alpha. Here, we provide evidence that both interferon-alpha and -gamma can enhance the secretion of 90K and augment the level of specific mRNA expression in 3 ovarian carcinoma cell lines (OVCAR-3, HTB-77 and SKOV-6). However, interferon-gamma leads to depletion of cellular 90K whereas interferon-alpha increases both secreted and cellular 90K levels. In equimolar concentrations, Interferon-alpha was always superior to interferon-gamma in augmenting 90K protein or mRNA levels. Combinations of TNF with interferon-gamma were highly synergistic both in reducing cell proliferation and in increasing 90K secretion and mRNA expression. This synergism was seen to a lesser extent with interferon-alpha.
authors.affiliation: Department of Obstetrics and Gynecology, Innsbruck University Hospital, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Marth
authors.forename: A
authors.initials: A
authors.lastname: Dreps
authors.forename: C
authors.initials: C
authors.lastname: Natoli
authors.forename: A G
authors.initials: AG
authors.lastname: Zeimet
authors.forename: T
authors.initials: T
authors.lastname: Lang
authors.forename: M
authors.initials: M
authors.lastname: Widschwendter
authors.forename: G
authors.initials: G
authors.lastname: Daxenbichler
authors.forename: A
authors.initials: A
authors.lastname: Ullrich
authors.forename: S
authors.initials: S
authors.lastname: Iacobelli
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D004357:Drug Synergism; D005260:Female; D006023:Glycoproteins; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D008074:Lipoproteins / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D016326:Extracellular Matrix Proteins
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D006023:Glycoproteins; D007370:Interferon Type I; D007371:Interferon-gamma; D008074:Lipoproteins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; C081856:LGALS3BP protein, human; D016326:Extracellular Matrix Proteins